Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 430

1.

Evidence for an association between intrahepatic vascular changes and the development of hepatopulmonary syndrome.

Lejealle C, Paradis V, Bruno O, de Raucourt E, Francoz C, Soubrane O, Lebrec D, Bedossa P, Valla D, Mal H, Vilgrain V, Durand F, Rautou PE.

Chest. 2018 Oct 4. pii: S0012-3692(18)32500-5. doi: 10.1016/j.chest.2018.09.017. [Epub ahead of print]

PMID:
30292761
2.

Effects of Long-term Norfloxacin Therapy in Patients With Advanced Cirrhosis.

Moreau R, Elkrief L, Bureau C, Perarnau JM, Thévenot T, Saliba F, Louvet A, Nahon P, Lannes A, Anty R, Hillaire S, Pasquet B, Ozenne V, Rudler M, Ollivier-Hourmand I, Robic MA, d'Alteroche L, Di Martino V, Ripault MP, Pauwels A, Grangé JD, Carbonell N, Bronowicki JP, Payancé A, Rautou PE, Valla D, Gault N, Lebrec D; NORFLOCIR Trial Investigators.

Gastroenterology. 2018 Aug 23. pii: S0016-5085(18)34891-1. doi: 10.1053/j.gastro.2018.08.026. [Epub ahead of print]

3.

Hepatocyte microvesicle levels improve prediction of mortality in patients with cirrhosis.

Payancé A, Silva-Junior G, Bissonnette J, Tanguy M, Pasquet B, Levi C, Roux O, Nekachtali O, Baiges A, Hernández-Gea V, Laouénan C, Lebrec D, Albuquerque M, Paradis V, Moreau R, Valla D, Durand F, Boulanger CM, Garcia-Pagan JC, Rautou PE.

Hepatology. 2018 Oct;68(4):1508-1518. doi: 10.1002/hep.29903. Epub 2018 May 21.

PMID:
29603327
4.

Non-invasive evaluation of portal hypertension using shear-wave elastography: analysis of two algorithms combining liver and spleen stiffness in 191 patients with cirrhosis.

Elkrief L, Ronot M, Andrade F, Dioguardi Burgio M, Issoufaly T, Zappa M, Roux O, Bissonnette J, Payancé A, Lebrec D, Francoz C, Soubrane O, Valla D, Durand F, Vilgrain V, Castera L, Rautou PE.

Aliment Pharmacol Ther. 2018 Mar;47(5):621-630. doi: 10.1111/apt.14488. Epub 2018 Jan 11.

PMID:
29322599
5.

A prospective study of the utility of plasma biomarkers to diagnose alcoholic hepatitis.

Bissonnette J, Altamirano J, Devue C, Roux O, Payancé A, Lebrec D, Bedossa P, Valla D, Durand F, Ait-Oufella H, Sancho-Bru P, Caballeria J, Ginès P, Boulanger CM, Bataller R, Rautou PE.

Hepatology. 2017 Aug;66(2):555-563. doi: 10.1002/hep.29080. Epub 2017 Jun 22.

PMID:
28120471
6.

Type I interferon signaling in systemic immune cells from patients with alcoholic cirrhosis and its association with outcome.

Weiss E, Rautou PE, Fasseu M, Giabicani M, de Chambrun M, Wan J, Minsart C, Gustot T, Couvineau A, Maiwall R, Hurtado-Nedelec M, Pilard N, Lebrec D, Valla D, Durand F, de la Grange P, Monteiro RC, Paugam-Burtz C, Lotersztajn S, Moreau R.

J Hepatol. 2017 May;66(5):930-941. doi: 10.1016/j.jhep.2016.12.008. Epub 2016 Dec 28.

PMID:
28040548
7.

Lack of clinical or haemodynamic rebound after abrupt interruption of beta-blockers in patients with cirrhosis.

Payancé A, Bissonnette J, Roux O, Elkrief L, Gault N, Francoz C, Nekachtali O, Soubrane O, Lebrec D, Valla D, Durand F, Rautou PE.

Aliment Pharmacol Ther. 2016 May;43(9):966-73. doi: 10.1111/apt.13577. Epub 2016 Mar 1.

8.

Prospective comparison of spleen and liver stiffness by using shear-wave and transient elastography for detection of portal hypertension in cirrhosis.

Elkrief L, Rautou PE, Ronot M, Lambert S, Dioguardi Burgio M, Francoz C, Plessier A, Durand F, Valla D, Lebrec D, Vilgrain V, Castéra L.

Radiology. 2015 May;275(2):589-98. doi: 10.1148/radiol.14141210. Epub 2014 Nov 28.

PMID:
25469784
9.

Effect of recombinant Factor VIIa on outcome of acute variceal bleeding: an individual patient based meta-analysis of two controlled trials.

Bendtsen F, D'Amico G, Rusch E, de Franchis R, Andersen PK, Lebrec D, Thabut D, Bosch J.

J Hepatol. 2014 Aug;61(2):252-9. doi: 10.1016/j.jhep.2014.03.035. Epub 2014 Apr 5.

PMID:
24713188
10.

Prednisolone with vs without pentoxifylline and survival of patients with severe alcoholic hepatitis: a randomized clinical trial.

Mathurin P, Louvet A, Duhamel A, Nahon P, Carbonell N, Boursier J, Anty R, Diaz E, Thabut D, Moirand R, Lebrec D, Moreno C, Talbodec N, Paupard T, Naveau S, Silvain C, Pageaux GP, Sobesky R, Canva-Delcambre V, Dharancy S, Salleron J, Dao T.

JAMA. 2013 Sep 11;310(10):1033-41. doi: 10.1001/jama.2013.276300.

PMID:
24026598
11.

Plasma fibroblast growth factor 23 concentration is increased and predicts mortality in patients on the liver-transplant waiting list.

Prié D, Forand A, Francoz C, Elie C, Cohen I, Courbebaisse M, Eladari D, Lebrec D, Durand F, Friedlander G.

PLoS One. 2013 Jun 25;8(6):e66182. doi: 10.1371/journal.pone.0066182. Print 2013.

12.

Gene- and exon-expression profiling reveals an extensive LPS-induced response in immune cells in patients with cirrhosis.

Gandoura S, Weiss E, Rautou PE, Fasseu M, Gustot T, Lemoine F, Hurtado-Nedelec M, Hego C, Vadrot N, Elkrief L, Lettéron P, Tellier Z, Pocidalo MA, Valla D, Lebrec D, Groyer A, Monteiro RC, de la Grange P, Moreau R.

J Hepatol. 2013 May;58(5):936-48. doi: 10.1016/j.jhep.2012.12.025. Epub 2013 Jan 12.

PMID:
23321315
13.

Editorial.

Stockbrugger R, Lebrec D.

Eur J Gastroenterol Hepatol. 2013 Jan;25(1):1. doi: 10.1097/MEG.0b013e32835caed8. No abstract available.

PMID:
23196723
14.

Severe hyponatremia is a better predictor of mortality than MELDNa in patients with cirrhosis and refractory ascites.

Sersté T, Gustot T, Rautou PE, Francoz C, Njimi H, Durand F, Valla D, Lebrec D, Moreau R.

J Hepatol. 2012 Aug;57(2):274-80. doi: 10.1016/j.jhep.2012.03.018. Epub 2012 Apr 17.

PMID:
22521353
15.

Abnormal plasma microparticles impair vasoconstrictor responses in patients with cirrhosis.

Rautou PE, Bresson J, Sainte-Marie Y, Vion AC, Paradis V, Renard JM, Devue C, Heymes C, Letteron P, Elkrief L, Lebrec D, Valla D, Tedgui A, Moreau R, Boulanger CM.

Gastroenterology. 2012 Jul;143(1):166-76.e6. doi: 10.1053/j.gastro.2012.03.040. Epub 2012 Mar 30.

PMID:
22465620
16.

Hemodynamics and pharmacokinetics of tezosentan, a dual endothelin receptor antagonist, in patients with cirrhosis.

Lebrec D, Bosch J, Jalan R, Dudley FJ, Jessic R, Moreau R, Garcia-Pagan JC, Mookerjee RP, Chiossi E, Van Giersbergen PL, Kusic-Pajic A, Dingemanse J.

Eur J Clin Pharmacol. 2012 May;68(5):533-41. doi: 10.1007/s00228-011-1157-6. Epub 2011 Nov 20.

PMID:
22101624
17.

Both IgA nephropathy and alcoholic cirrhosis feature abnormally glycosylated IgA1 and soluble CD89-IgA and IgG-IgA complexes: common mechanisms for distinct diseases.

Tissandié E, Morelle W, Berthelot L, Vrtovsnik F, Daugas E, Walker F, Lebrec D, Trawalé JM, Francoz C, Durand F, Moura IC, Paradis V, Moreau R, Monteiro RC.

Kidney Int. 2011 Dec;80(12):1352-63. doi: 10.1038/ki.2011.276. Epub 2011 Aug 24.

18.

Early TIPS with covered stents in high-risk patients with cirrhosis presenting with variceal bleeding: are we ready to dive into the deep end of the pool?

Thabut D, Rudler M, Lebrec D.

J Hepatol. 2011 Nov;55(5):1148-9. doi: 10.1016/j.jhep.2011.05.013. Epub 2011 Jun 25.

19.

Changes in autophagic response in patients with chronic hepatitis C virus infection.

Rautou PE, Cazals-Hatem D, Feldmann G, Mansouri A, Grodet A, Barge S, Martinot-Peignoux M, Duces A, Bièche I, Lebrec D, Bedossa P, Paradis V, Marcellin P, Valla D, Asselah T, Moreau R.

Am J Pathol. 2011 Jun;178(6):2708-15. doi: 10.1016/j.ajpath.2011.02.021.

20.

Neutralization of lipopolysaccharide effects in liver diseases, the quest for the Holy Grail.

Galbois A, Thabut D, Moreau R, Lebrec D.

Hepatology. 2011 Jul;54(1):376. doi: 10.1002/hep.24186. Epub 2011 May 2. No abstract available.

PMID:
21538432
21.

Detection of bacterial DNA in serum and ascitic fluid of asymptomatic outpatients with cirrhosis and non-neutrocytic ascites.

Sersté T, Bert F, Leflon-Guibout V, Chauvet C, Marcon E, Asselah T, Francoz C, Durand F, Lebrec D, Valla D, Moreau R, Nicolas-Chanoine MH.

Liver Int. 2011 Apr;31(4):494-8. doi: 10.1111/j.1478-3231.2011.02448.x. Epub 2011 Jan 30.

PMID:
21382159
22.

Beta-blockers cause paracentesis-induced circulatory dysfunction in patients with cirrhosis and refractory ascites: a cross-over study.

Sersté T, Francoz C, Durand F, Rautou PE, Melot C, Valla D, Moreau R, Lebrec D.

J Hepatol. 2011 Oct;55(4):794-9. doi: 10.1016/j.jhep.2011.01.034. Epub 2011 Feb 24.

PMID:
21354230
23.

Glycogen synthase kinase 3 involvement in the excessive proinflammatory response to LPS in patients with decompensated cirrhosis.

Coant N, Simon-Rudler M, Gustot T, Fasseu M, Gandoura S, Ragot K, Abdel-Razek W, Thabut D, Lettéron P, Ogier-Denis E, Ouziel R, Devière J, Lizard G, Tellier Z, Lebrec D, Moreau R.

J Hepatol. 2011 Oct;55(4):784-93. doi: 10.1016/j.jhep.2010.12.039. Epub 2011 Feb 18.

PMID:
21334395
24.

Noninvasive assessment of portal hypertension in patients with cirrhosis.

Thabut D, Moreau R, Lebrec D.

Hepatology. 2011 Feb;53(2):683-94. doi: 10.1002/hep.24129. Review.

PMID:
21274889
25.

Bleeding in patients with Budd-Chiari syndrome.

Rautou PE, Douarin L, Denninger MH, Escolano S, Lebrec D, Moreau R, Vidaud M, Itzykson R, Moucari R, Bezeaud A, Valla D, Plessier A.

J Hepatol. 2011 Jan;54(1):56-63. doi: 10.1016/j.jhep.2010.06.019. Epub 2010 Aug 20.

PMID:
20889223
26.

Diagnostic performance of Baveno IV criteria in cirrhotic patients with upper gastrointestinal bleeding: analysis of the F7 liver-1288 study population.

Thabut D, D'Amico G, Tan P, De Franchis R, Fabricius S, Lebrec D, Bosch J, Bendtsen F.

J Hepatol. 2010 Dec;53(6):1029-34. doi: 10.1016/j.jhep.2010.06.012. Epub 2010 Aug 12.

PMID:
20817301
27.

Autophagy in liver diseases.

Rautou PE, Mansouri A, Lebrec D, Durand F, Valla D, Moreau R.

J Hepatol. 2010 Dec;53(6):1123-34. doi: 10.1016/j.jhep.2010.07.006. Epub 2010 Aug 1. Review.

28.

Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites.

Sersté T, Melot C, Francoz C, Durand F, Rautou PE, Valla D, Moreau R, Lebrec D.

Hepatology. 2010 Sep;52(3):1017-22. doi: 10.1002/hep.23775.

PMID:
20583214
29.

In vivo hepatic endoplasmic reticulum stress in patients with chronic hepatitis C.

Asselah T, Bièche I, Mansouri A, Laurendeau I, Cazals-Hatem D, Feldmann G, Bedossa P, Paradis V, Martinot-Peignoux M, Lebrec D, Guichard C, Ogier-Denis E, Vidaud M, Tellier Z, Soumelis V, Marcellin P, Moreau R.

J Pathol. 2010 Jul;221(3):264-74. doi: 10.1002/path.2703.

PMID:
20527020
30.

Pentoxifylline does not decrease short-term mortality but does reduce complications in patients with advanced cirrhosis.

Lebrec D, Thabut D, Oberti F, Perarnau JM, Condat B, Barraud H, Saliba F, Carbonell N, Renard P, Ramond MJ, Moreau R, Poynard T; Pentocir Group.

Gastroenterology. 2010 May;138(5):1755-62. doi: 10.1053/j.gastro.2010.01.040. Epub 2010 Jan 25.

PMID:
20102716
31.

The spectrum of renal lesions in patients with cirrhosis: a clinicopathological study.

Trawalé JM, Paradis V, Rautou PE, Francoz C, Escolano S, Sallée M, Durand F, Valla D, Lebrec D, Moreau R.

Liver Int. 2010 May;30(5):725-32. doi: 10.1111/j.1478-3231.2009.02182.x. Epub 2009 Dec 18.

PMID:
20040048
32.

Severe sepsis in cirrhosis.

Gustot T, Durand F, Lebrec D, Vincent JL, Moreau R.

Hepatology. 2009 Dec;50(6):2022-33. doi: 10.1002/hep.23264. Review. Erratum in: Hepatology. 2010 Feb;51(2):725.

PMID:
19885876
33.

Levels and initial course of serum alanine aminotransferase can predict outcome of patients with Budd-Chiari syndrome.

Rautou PE, Moucari R, Cazals-Hatem D, Escolano S, Denié C, Douarin L, Francoz C, Durand F, Ozenne V, Imbert A, Moreau R, Lebrec D, Plessier A, Valla D.

Clin Gastroenterol Hepatol. 2009 Nov;7(11):1230-5. doi: 10.1016/j.cgh.2009.06.011. Epub 2009 Jun 26.

PMID:
19560555
34.

[Progress in portal hypertension].

Lebrec D, Moreau R.

Gastroenterol Clin Biol. 2009 Aug-Sep;33(8-9):799-810. doi: 10.1016/j.gcb.2009.04.001. Epub 2009 Jun 21. Review. French.

35.

Protein array technology to investigate cytokine production by monocytes from patients with advanced alcoholic cirrhosis: An ex vivo pilot study.

Tazi KA, Quioc JJ, Abdel-Razek W, Tellier Z, Guichard C, Ogier-Denis E, Lebrec D, Moreau R.

Hepatol Res. 2009 Jul;39(7):706-15. doi: 10.1111/j.1872-034X.2009.00498.x. Epub 2009 Mar 15.

PMID:
19473436
36.

Cirrhosis ameliorates monocrotaline-induced pulmonary hypertension in rats.

Le Pavec J, Perros F, Eddahibi S, Decante B, Dorfmuller P, Sitbon O, Lebrec D, Humbert M, Mazmanian M, Herve P.

Eur Respir J. 2009 Sep;34(3):731-9. doi: 10.1183/09031936.00006508. Epub 2009 Mar 26.

37.

Ex vivo effects of high-density lipoprotein exposure on the lipopolysaccharide-induced inflammatory response in patients with severe cirrhosis.

Galbois A, Thabut D, Tazi KA, Rudler M, Mohammadi MS, Bonnefont-Rousselot D, Bennani H, Bezeaud A, Tellier Z, Guichard C, Coant N, Ogier-Denis E, Moreau R, Lebrec D.

Hepatology. 2009 Jan;49(1):175-84. doi: 10.1002/hep.22582.

PMID:
19053046
38.

Possible mechanisms involved in the discrepancy of hepatic and aortic endothelial nitric oxide synthases during the development of cirrhosis in rats.

Mohammadi MS, Thabut D, Cazals-Hatem D, Galbois A, Rudler M, Bonnefont-Rousselot D, Moreau R, Lebrec D, Tazi KA.

Liver Int. 2009 May;29(5):692-700. doi: 10.1111/j.1478-3231.2008.01909.x. Epub 2009 Nov 27.

PMID:
19040541
39.

Acute kidney injury: new concepts. Hepatorenal syndrome: the role of vasopressors.

Moreau R, Lebrec D.

Nephron Physiol. 2008;109(4):p73-9. doi: 10.1159/000142939. Epub 2008 Sep 18. Review.

PMID:
18802378
40.

Acute liver cell damage in patients with anorexia nervosa: a possible role of starvation-induced hepatocyte autophagy.

Rautou PE, Cazals-Hatem D, Moreau R, Francoz C, Feldmann G, Lebrec D, Ogier-Denis E, Bedossa P, Valla D, Durand F.

Gastroenterology. 2008 Sep;135(3):840-8, 848.e1-3. doi: 10.1053/j.gastro.2008.05.055. Epub 2008 May 28.

PMID:
18644371
41.

[Pathophysiology and prognosis of refractory ascites in patients with cirrhosis].

Moreau R, Lebrec D.

Gastroenterol Clin Biol. 2008 Aug-Sep;32(8-9):705-9. doi: 10.1016/j.gcb.2008.05.004. Epub 2008 Jul 10. Review. French. No abstract available.

42.

Portopulmonary hypertension: survival and prognostic factors.

Le Pavec J, Souza R, Herve P, Lebrec D, Savale L, Tcherakian C, Jaïs X, Yaïci A, Humbert M, Simonneau G, Sitbon O.

Am J Respir Crit Care Med. 2008 Sep 15;178(6):637-43. doi: 10.1164/rccm.200804-613OC. Epub 2008 Jul 10.

PMID:
18617641
43.

[Refractory ascites in patients with cirrhosis].

Moreau R, Durand F, Lebrec D.

Gastroenterol Clin Biol. 2008 Aug-Sep;32(8-9):703-4. doi: 10.1016/j.gcb.2008.05.001. Epub 2008 Jul 9. French. No abstract available.

44.

[Management of refractory ascites with the exception of the transjugular intrahepatic portosystemic shunt (TIPS) and liver transplantation].

Moreau R, Lebrec D.

Gastroenterol Clin Biol. 2008 Aug-Sep;32(8-9):710-6. doi: 10.1016/j.gcb.2008.05.005. Epub 2008 Jul 7. Review. French. No abstract available.

45.

[Management of refractory ascites by the transjugular intrahepatic portosystemic shunt (TIPS)].

Lebrec D, Moreau R.

Gastroenterol Clin Biol. 2008 Aug-Sep;32(8-9):717-20. doi: 10.1016/j.gcb.2008.05.006. Epub 2008 Jun 30. Review. French. No abstract available.

46.

Screening for esophageal varices: Endoscopy, other tools, or endoscopy and other tools?

Thabut D, Moreau R, Lebrec D.

Hepatology. 2008 May;47(5):1434-6. doi: 10.1002/hep.22315. No abstract available.

PMID:
18435464
47.

Incidence and characteristics of type 2 hepatorenal syndrome in patients with cirrhosis and refractory ascites.

Sersté T, Lebrec D, Valla D, Moreau R.

Acta Gastroenterol Belg. 2008 Jan-Mar;71(1):9-14.

PMID:
18396743
48.

Recombinant factor VIIa for variceal bleeding in patients with advanced cirrhosis: A randomized, controlled trial.

Bosch J, Thabut D, Albillos A, Carbonell N, Spicak J, Massard J, D'Amico G, Lebrec D, de Franchis R, Fabricius S, Cai Y, Bendtsen F; International Study Group on rFVIIa in UGI Hemorrhage.

Hepatology. 2008 May;47(5):1604-14. doi: 10.1002/hep.22216.

PMID:
18393319
49.
50.

Model for end-stage liver disease score and systemic inflammatory response are major prognostic factors in patients with cirrhosis and acute functional renal failure.

Thabut D, Massard J, Gangloff A, Carbonell N, Francoz C, Nguyen-Khac E, Duhamel C, Lebrec D, Poynard T, Moreau R.

Hepatology. 2007 Dec;46(6):1872-82.

PMID:
17972337

Supplemental Content

Loading ...
Support Center